Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Total Liabilities (2016 - 2026)

Mimedx's Total Liabilities history spans 17 years, with the latest figure at $65.7 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 2.81% to $65.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $65.7 million, a 2.81% decrease, with the full-year FY2025 number at $86.1 million, up 21.6% from a year prior.
  • Total Liabilities hit $65.7 million in Q1 2026 for Mimedx, down from $86.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for MDXG hit a ceiling of $99.8 million in Q3 2022 and a floor of $62.1 million in Q2 2024.
  • Historically, Total Liabilities has averaged $82.0 million across 5 years, with a median of $86.1 million in 2025.
  • Biggest five-year swings in Total Liabilities: tumbled 35.64% in 2024 and later increased 27.29% in 2025.
  • Tracing MDXG's Total Liabilities over 5 years: stood at $96.9 million in 2022, then fell by 0.61% to $96.3 million in 2023, then decreased by 26.49% to $70.8 million in 2024, then increased by 21.6% to $86.1 million in 2025, then decreased by 23.65% to $65.7 million in 2026.
  • Business Quant data shows Total Liabilities for MDXG at $65.7 million in Q1 2026, $86.1 million in Q4 2025, and $80.0 million in Q3 2025.